公开(公告)号：US20230302040A1

公开(公告)日：2023-09-28

申请号：US18143370

申请日：2023-05-04

申请人： OSAKA UNIVERSITY ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

发明人： Hiroyuki TANAKA ,  Hideki YOSHIKAWA ,  Hideki MOCHIZUKI ,  Tsuyoshi MURASE ,  Tsutomu SASAKI ,  Kousuke BABA ,  Toru IWAHASHI ,  Mitsuru NAIKI

IPC分类号： A61K31/714 ,  A61P25/28 ,  A61K9/00

CPC分类号： A61K31/714 ,  A61P25/28 ,  A61K9/0019

摘要： An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

公开(公告)号：US20210008092A1

公开(公告)日：2021-01-14

申请号：US16907913

申请日：2020-06-22

申请人： OSAKA UNIVERSITY ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

发明人： Hiroyuki TANAKA ,  Hideki YOSHIKAWA ,  Hideki MOCHIZUKI ,  Tsuyoshi MURASE ,  Tsutomu SASAKI ,  Kousuke BABA ,  Toru IWAHASHI ,  Mitsuru NAIKI

IPC分类号： A61K31/714 ,  A61K9/00 ,  A61P25/28

摘要： A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin B12 to a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin B12 to the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B12.

公开(公告)号：US20220273692A1

公开(公告)日：2022-09-01

申请号：US17748553

申请日：2022-05-19

申请人： OSAKA UNIVERSITY ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

发明人： Hiroyuki TANAKA ,  Hideki YOSHIKAWA ,  Hideki MOCHIZUKI ,  Tsuyoshi MURASE ,  Tsutomu SASAKI ,  Kousuke BABA ,  Toru IWAHASHI ,  Mitsuru NAIKI

IPC分类号： A61K31/714 ,  A61P25/28 ,  A61K9/00

摘要： An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

公开(公告)号：US20200023045A1

公开(公告)日：2020-01-23

申请号：US16486768

申请日：2018-02-20

申请人： OSAKA UNIVERSITY ,  FUNPEP CO., LTD.

发明人： Munehisa SHIMAMURA ,  Tomohiro KAWANO ,  Hironori NAKAGAMI ,  Ryuichi MORISHITA ,  Hideki MOCHIZUKI ,  Akiko TENMA ,  Takako EHARA

IPC分类号： A61K39/00 ,  A61K47/42 ,  A61P9/10 ,  A61P7/02 ,  C07K14/435 ,  A61K39/39

摘要： Provided is an immunogenic composition comprising an antigenic peptide capable of inducing production of a neutralizing antibody against S100A9 and a carrier protein. The immunogenic composition can be used as a highly safe antithrombotic vaccine having antithrombotic effect without a long-term bleeding risk and is useful for the prevention of a disease associated with thrombus formation in which platelet aggregation is involved, particularly for the prevention of recurrent ischemic stroke.

公开(公告)号：US20200172903A1

公开(公告)日：2020-06-04

申请号：US16616743

申请日：2018-07-03

申请人： OSAKA UNIVERSITY ,  DAIICHI SANKYO COMPANY, LIMITED

发明人： Masayuki NAKAMORI ,  Hideki MOCHIZUKI ,  Satoshi OBIKA ,  Makoto KOIZUMI ,  Akifumi NAKAMURA ,  Kiyosumi TAKAISHI ,  Yumiko ASAHI

IPC分类号： C12N15/113 ,  A61P25/16 ,  A61P25/28

摘要： The objective of the present invention is to provide nucleic acid therapeutics which exhibits more excellent effect and which shows a substantivity for a prolonged period to suppress an expression of α-synuclein. The oligonucleotide or a pharmacologically acceptable salt thereof according to the present invention is characterized in comprising at least one 2′-O,4′-C-ethylene nucleoside, wherein the oligonucleotide can hybridize with α-synuclein gene, has an activity to suppress an expression of the α-synuclein gene, and is complementary to the α-synuclein gene, 5′ end of the oligonucleotide is a nucleotide complementary to the specific nucleotide, the oligonucleotide is complementary to at least a part of SEQ ID NO: 1, and the oligonucleotide has a length of 13 or more and 15 or less nucleotides.

公开(公告)号：US20190008886A1

公开(公告)日：2019-01-10

申请号：US16068163

申请日：2017-01-05

申请人： OSAKA UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

发明人： Masayuki NAKAMORI ,  Hideki MOCHIZUKI ,  Satoshi OBIKA ,  Takanori YOKOTA ,  Tetuya NAGATA ,  Yuya KASAHARA

IPC分类号： A61K31/712 ,  C12N15/113 ,  C07K14/47 ,  A61P25/28 ,  A61P25/16

摘要： The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of α-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an α-synudein gene, has activity for inhibiting expression of the α-synudein gene, and is complementary to the α-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.